Amyloidosis Fellowship Program

The call for applications for ISA 2026-2027 Fellowships is now open.

Apply HERE

ISA awards a limited number of amyloidosis fellowships each year, with a focus on clinical training in all types of amyloidosis. The number of fellowships will depend on funds available.

In 2021-2024, ISA collaborated with Pfizer to offer cardiac amyloidosis fellowships. Starting with 2024-2025 fellowships, ISA has expanded its fellowship program to include all kinds of amyloidosis and multiple sponsors. With this new, expanded program, potential fellows and their host institutions negotiate the details of fellowships, then jointly apply to ISA for a fellowship grant.

The goals of ISA’s fellowship program are to:

    • train physicians to diagnose and manage all types of amyloidosis, especially ATTR and AL amyloidosis
    • develop the next generation of leading clinicians in the amyloidosis field
    • encourage collaboration among institutions to enhance to address unanswered research questions in the field.
    • provide a training experience and mentoring on the conduct of rigorously designed clinical research through participation in amyloidosis-related investigations.

Fellows are expected to be part of ISA educational efforts and impart their acquired knowledge and experience in diagnosing and managing amyloidosis, all of which should translate into decreased delays in diagnosis, more accurate diagnoses, and improved management of amyloidosis in their home regions or under-served areas.

Fellowship applicants should hold an MD degree or equivalent. Preference will be given to those who have completed or are about to complete a relevant fellowship (cardiology, hematology, neurology, etc.).  Some clinical experience, especially with amyloidosis, is preferred.

The host institution’s amyloidosis center or program must have specialists (e.g. at a minimum cardiologists, hematologists) with expertise in diagnosing and treating amyloidosis. Expertise in at least two additional disciplines from the following list is desirable: neurology, pathology, nephrology, radiology, and organ transplantation. The institution’s amyloidosis program should have a volume of patients such that a fellow would see a mix of types of amyloidosis and at least 15 patients with amyloidosis per week (new and follow-up on an outpatient basis).

Preference will be given to centers with a track record of clinical trials, research, and publications in the amyloidosis field. Ideally, the host institution will offer the fellow opportunities to participate in research programs.